journal
https://read.qxmd.com/read/31908559/systematic-review-genetic-associations-for-prognostic-factors-of-urinary-bladder-cancer
#1
REVIEW
Nadezda Lipunova, Anke Wesselius, Kar K Cheng, Frederik J van Schooten, Jean-Baptiste Cazier, Richard T Bryan, Maurice P Zeegers
Introduction: Many germline associations have been reported for urinary bladder cancer (UBC) outcomes and prognostic characteristics. It is unclear whether there are overlapping genetic patterns for various prognostic endpoints. We aimed to review contemporary literature on genetic associations with UBC prognostic outcomes and to identify potential overlap in reported genes. Methods: EMBASE, MEDLINE, and PubMed databases were queried for relevant articles in English language without date restrictions...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/31903024/behavioural-response-alteration-in-caenorhabditis-elegans-to-urine-after-surgical-removal-of-cancer-nematode-nose-n-nose-for-postoperative-evaluation
#2
JOURNAL ARTICLE
Hirotake Kusumoto, Kotaro Tashiro, Syunji Shimaoka, Koichiro Tsukasa, Yukiko Baba, Saori Furukawa, Junichiro Furukawa, Toyokuni Suenaga, Masaki Kitazono, Sadao Tanaka, Toru Niihara, Takaaki Hirotsu, Takayuki Uozumi
The technique used for cancer monitoring is essential for effective cancer therapy. Currently, several methods such as diagnostic imaging and biochemical markers have been used for cancer monitoring, but these are invasive and show low sensitivity. A previous study reported that Caenorhabditis elegans sensitively discriminated patients with cancer from healthy subjects, based on the smell of a urine sample. However, whether C. elegans olfaction can detect the removal of cancerous tumours remains unknown. This study was conducted to examine C...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/31555051/detection-of-micro-invasion-in-sudanese-oral-verrucous-carcinoma-samples-using-syndecan-1-stain
#3
JOURNAL ARTICLE
Akb Elhassan, A M Suleiman, Nia El Dawi, Sofia B Mohamed
Aim: Verrucous carcinoma (VC) is a low-grade rare variant of squamous cell carcinoma (SCC). Syndecan-1 (CD138) is a heparan sulfate proteoglycan which participates in cell-to-cell adhesion and cell-matrix interaction. Being misled by the apparent non-aggressive nature of VC, some clinicians and pathologists believe that this tumor is not an aggressive tumor, not realizing the fact that some of these lesions may contain nests or foci of well-differentiated SCC. This study aimed to assess syndecan-1 expression of VC and detection of micro-invasion in VC using syndecan-1 immunohistochemical (IHC) stain...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/31308780/chemotherapy-resistance-in-advanced-ovarian-cancer-patients
#4
REVIEW
Ruchika Pokhriyal, Roopa Hariprasad, Lalit Kumar, Gururao Hariprasad
Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/31236012/multivariate-index-assay-is-superior-to-ca125-and-he4-testing-in-detection-of-ovarian-malignancy-in-african-american-women
#5
JOURNAL ARTICLE
Charles Dunton, Rowan G Bullock, Herbert Fritsche
Objective: To review and analyze the serum values of risk of ovarian malignancy algorithm (ROMA) and multivariate index assay (MIA) in subgroups of women who underwent surgery for adnexal masses to determine sensitivity, specificity, and positive and negative predictive values for the detection of malignancy in different ethnic populations. Methods: Serum samples from 2 prospective trials of 1029 women in which 274 women diagnosed with malignancy were analyzed for ROMA scores and MIA results...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/31217693/following-chemotherapy-serum-cytokine-tumor-necrosis-factor-interleukin-2-interleukin-11-immunoglobulin-complement-vascular-endothelial-growth-factor-levels-and-the-systemic-symptoms-like-capillary-leak-syndrome
#6
JOURNAL ARTICLE
Havva Keskin, Kenan Cadirci, Ahmet Demirkazik, Hakan Akbulut, Bulent Yalcin
Several problems such as myalgia, arthralgia, fever, dyspnea, generalized edema, and pleural effusion can occur in cancer patients following the chemotherapy, especially at the first cycle of the first chemotherapy treatment. Although it is assumed that some cytokines are associated with the development of these symptoms and signs, their pathophysiology has not been discovered completely yet. They are usually mild, but they may rarely progress to the severe stage of "Systemic Capillary Leak Syndrome" with a high mortality rate...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/31210736/assessment-of-the-spatial-heterogeneity-of-breast-cancers-associations-between-computed-tomography-and-immunohistochemistry
#7
JOURNAL ARTICLE
David K Woolf, Sonia P Li, Simone Detre, Alison Liu, Andrew Gogbashian, Ian C Simcock, James Stirling, Michael Kosmin, Gary J Cook, Muhammad Siddique, Mitch Dowsett, Andreas Makris, Vicky Goh
Background: Tumour heterogeneity is considered an important mechanism of treatment failure. Imaging-based assessment of tumour heterogeneity is showing promise but the relationship between these mathematically derived measures and accepted 'gold standards' of tumour biology such as immunohistochemical measures is not established. Methods: A total of 20 women with primary breast cancer underwent a research dynamic contrast-enhanced computed tomography prior to treatment with data being available for 15 of these...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/30886526/rbbp6-is-abundantly-expressed-in-human-cervical-carcinoma-and-may-be-implicated-in-its-malignant-progression
#8
JOURNAL ARTICLE
Zodwa Dlamini, Thokozile Ledwaba, Rodney Hull, Sarala Naicker, Zukile Mbita
RBBP6 is a novel gene encoding splicing-associated proteins. There are 3 protein isoforms (isoforms 1-3). RBBP6 isoforms 1 has been shown to interact with both p53 and Rb. It also plays a role in the induction of apoptosis and the regulation of the cell cycle. The expression of RBBP6 has been documented in several cancers but RBBP6 expression in cervical cancer has not been well studied. The aim of this study was to establish expression levels and tissue distribution of the RBBP6 gene products at both protein and messenger RNA (mRNA) levels in cervical cancer by immunocytochemistry and in situ hybridization (ISH)...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/30833816/urine-biomarkers-for-the-early-detection-of-ovarian-cancer-are-we-there-yet
#9
REVIEW
Kelly Grayson, Ebony Gregory, Ghazala Khan, Barbara-Ann Guinn
Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; however, there is usually a masking of symptoms which leads to an often late-stage diagnosis and correspondingly poor survival rate. Current diagnostic methods are invasive and consist of a pelvic examination, transvaginal ultrasonography, and blood tests to detect cancer antigen 125 (CA125)...
2019: Biomarkers in Cancer
https://read.qxmd.com/read/35237085/a-combinatorial-proteomic-biomarker-assay-to-detect-ovarian-cancer-in-women
#10
JOURNAL ARTICLE
Meredith C Henderson, Michael Silver, Sherri Borman, Quynh Tran, Elias Letsios, Rao Mulpuri, David E Reese, Judith K Wolf
Ovarian cancer is often fatal and incidence in the general population is low, underscoring the necessity (and the challenges) for advancements in screening and early detection. The goal of this study was to design a serum-based biomarker panel and corresponding multivariate algorithm that can be used to accurately detect ovarian cancer. A combinatorial protein biomarker assay (CPBA) that uses CA125, HE4, and 3 tumor-associated autoantibodies resulted in an area under the curve of 0.98. The CPBA Ov algorithm was trained using subjects who were suspected to have gynecological cancer and were scheduled for surgery...
2018: Biomarkers in Cancer
https://read.qxmd.com/read/30911223/vasodilator-stimulated-phosphoprotein-biomarkers-are-associated-with-invasion-and-metastasis-in-colorectal-cancer
#11
JOURNAL ARTICLE
Giovanni M Pitari, Paolo Cotzia, Mehboob Ali, Ruth Birbe, Wendy Rizzo, Alessandro Bombonati, Juan Palazzo, Charalambos Solomides, Anthony P Shuber, Frank A Sinicrope, David S Zuzga
Background and Aims: The benefit of adjuvant chemotherapy for stage II colorectal cancer (CRC) patients remains unclear, emphasizing the need for improved prognostic biomarkers to identify patients at risk of metastatic recurrence. To address this unmet clinical need, we examined the expression and phosphorylation status of the vasodilator-stimulated phosphoprotein (VASP) in CRC tumor progression. VASP, a processive actin polymerase, promotes the formation of invasive membrane structures leading to extracellular matrix remodeling and tumor invasion...
2018: Biomarkers in Cancer
https://read.qxmd.com/read/30573999/corrigendum
#12
JOURNAL ARTICLE
(no author information available yet)
[This corrects the article DOI: 10.1177/1179299X17737301.].
2018: Biomarkers in Cancer
https://read.qxmd.com/read/29977116/circulating-micrornas-as-biomarkers-in-diffuse-large-b-cell-lymphoma-a-pilot-prospective-longitudinal-clinical-study
#13
JOURNAL ARTICLE
Céline Bouvy, Adeline Wannez, Fabienne George, Carlos Graux, Christian Chatelain, Jean-Michel Dogné
Objectives: Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous in terms of phenotype and treatment response in patients. These characteristics make the prognosis difficult to establish and hinder the use of new personalized treatments in clinical practice. In this context, there is currently a need to define new biomarkers enabling a better definition of DLBCL subtypes, prognosis evaluation, and an overview of the resistance to chemotherapeutics. The aim of this study was to evaluate the use of microRNAs found in plasma from patients with DLBCL as biomarkers of tumor evolution in these patients...
2018: Biomarkers in Cancer
https://read.qxmd.com/read/29872358/clean-colorectum-at-diagnostic-colonoscopy-subsequent-detection-of-extracolonic-malignancies-by-plasma-protein-biomarkers
#14
JOURNAL ARTICLE
Michael Wilhelmsen, Ib J Christensen, Lars N Jørgensen, Mogens R Madsen, Jesper Vilandt, Thore Hillig, Michael Klærke, Knud T Nielsen, Søren Laurberg, Susan Gawel, Xiaoping Yang, Gerard Davis, Anne Meike Heijboer, Frans Martens, Hans J Nielsen
INTRODUCTION: Most of the subjects undergoing diagnostic colonoscopy do not have neoplastic bowel lesions. Potentially, some of the symptoms may therefore be caused by extracolonic malignancy, and subjects with persisting symptoms may need subsequent examinations. Blood-based, cancer-associated biomarkers may aid in directing the examinations for other specific malignant diseases. METHODS: EDTA plasma samples available from a previous prospective study of subjects undergoing diagnostic colonoscopy were used for analysis of 18 protein biomarkers...
2018: Biomarkers in Cancer
https://read.qxmd.com/read/29497340/data-mining-of-small-rna-seq-suggests-an-association-between-prostate-cancer-and-altered-abundance-of-5-transfer-rna-halves-in-seminal-fluid-and-prostatic-tissues
#15
JOURNAL ARTICLE
Joseph M Dhahbi, Hani Atamna, Luke A Selth
Extracellular RNAs are gaining clinical interest as biofluid-based noninvasive markers for diseases, especially cancer. In particular, derivatives of transfer RNA (tRNA) are emerging as a new class of small-noncoding RNAs with high biomarker potential. We and others previously reported alterations in serum levels of specific tRNA halves in disease states including cancer. Here, we explored seminal fluid for tRNA halves as potential markers of prostate cancer. We found that 5' tRNA halves are abundant in seminal fluid and are elevated in prostate cancer relative to noncancer patients...
2018: Biomarkers in Cancer
https://read.qxmd.com/read/29467585/integrating-circulating-immunological-and-sputum-biomarkers-for-the-early-detection-of-lung-cancer
#16
JOURNAL ARTICLE
Jian Su, Qixin Leng, Yanli Lin, Jie Ma, Fangran Jiang, Cheng-Ju Lee, HongBin Fang, Feng Jiang
We have demonstrated that assessments of microRNA (miRNA) expressions in circulating peripheral blood mononucleated cell (PBMC) and sputum specimens, respectively, may help diagnose lung cancer. To assess the individual and combined analysis of the miRNAs across the different body fluids for lung cancer early detection, we analyse a panel of 3 sputum miRNAs (miRs-21, 31, and 210) and a panel of 2 PBMC miRNAs (miRs-19b-3p and 29b-3p) in a discovery cohort of 68 patients with lung cancer and 66 cancer-free smokers...
2018: Biomarkers in Cancer
https://read.qxmd.com/read/29343995/humanmethylation450k-array-identified-biomarkers-predict-tumour-recurrence-progression-at-initial-diagnosis-of-high-risk-non-muscle-invasive-bladder-cancer
#17
JOURNAL ARTICLE
Mark O Kitchen, Richard T Bryan, Richard D Emes, Christopher J Luscombe, K K Cheng, Maurice P Zeegers, Nicholas D James, Lyndon M Gommersall, Anthony A Fryer
BACKGROUND: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers, particularly DNA methylation, have been reported as predictive of tumour/patient outcomes in numerous solid organ and haematologic malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment...
2018: Biomarkers in Cancer
https://read.qxmd.com/read/35237086/mir-486-3p-mir-139-5p-and-mir-21-as-biomarkers-for-the-detection-of-oral-tongue-squamous-cell-carcinoma
#18
JOURNAL ARTICLE
Zujian Chen, Tianwei Yu, Robert J Cabay, Yi Jin, Ishrat Mahjabeen, Xianghong Luan, Lei Huang, Yang Dai, Xiaofeng Zhou
Oral tongue squamous cell carcinoma (TSCC) is a complex disease with extensive genetic and epigenetic defects, including microRNA deregulation. The aims of the present study were to test the feasibility of performing the microRNA profiling analysis on archived TSCC specimens and to assess the potential diagnostic utility of the identified microRNA biomarkers for the detection of TSCC. TaqMan array-based microRNA profiling analysis was performed on 10 archived TSCC samples and their matching normal tissues. A panel of 12 differentially expressed microRNAs was identified...
2017: Biomarkers in Cancer
https://read.qxmd.com/read/29147078/long-noncoding-rnas-as-a-key-player-in-hepatocellular-carcinoma
#19
REVIEW
Mrigaya Mehra, Ranjit Chauhan
Hepatocellular carcinoma (HCC) is a major malignancy in the liver and has emerged as one of the main cancers in the world with a high mortality rate. However, the molecular mechanisms of HCC are still poorly understood. Long noncoding RNAs (lncRNAs) have recently come to the forefront as functional non-protein-coding RNAs that are involved in a variety of cellular processes ranging from maintaining the structural integrity of chromosomes to gene expression regulation in a spatiotemporal manner. Many recent studies have reported the involvement of lncRNAs in HCC which has led to a better understanding of the underlying molecular mechanisms operating in HCC...
2017: Biomarkers in Cancer
https://read.qxmd.com/read/29085239/more-accurate-oral-cancer-screening-with-fewer-salivary-biomarkers
#20
JOURNAL ARTICLE
James Michael Menke, Md Shahidul Ahsan, Suan Phaik Khoo
Signal detection and Bayesian inferential tools were applied to salivary biomarkers to improve screening accuracy and efficiency in detecting oral squamous cell carcinoma (OSCC). Potential cancer biomarkers are identified by significant differences in assay concentrations, receiver operating characteristic areas under the curve (AUCs), sensitivity, and specificity. However, the end goal is to report to individual patients their risk of having disease given positive or negative test results. Likelihood ratios (LRs) and Bayes factors (BFs) estimate evidential support and compile biomarker information to optimize screening accuracy...
2017: Biomarkers in Cancer
journal
journal
47141
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.